ASCO 2020: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping…
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping…
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol…
By analysing tumours from patients treated with immunotherapy for advanced kidney cancer in three clinical…
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients…
Researchers at Fox Chase Cancer Center, USA, along with an international team of investigators, have…
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was…
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune…
Front-line therapy with the immune checkpoint inhibitor pembrolizumab doubled progression-free survival vs chemotherapy in patients…
A new type of test that uses complex sugars to detect prostate cancer earlier and…
A team of researchers led by Worcester Polytechnic Institute (WPI), USA, Provost Wole Soboyejo has…